ENHERTU (fam-trastuzumab deruxtecan-nxki) gets US FDA nod for HER2-positive advanced gastric cancer
The results from the DESTINY-Gastric01 trial showed a 41 per cent improvement in survival and a response rate more than three…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.